[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517542":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":31,"responsibleParty":48,"collaborators":51,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":51,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":34,"whyStopped":51,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ascorbate","EXPERIMENTAL","For patients with baseline serum Vitamin C concentration \\\u003C 65 μmol\u002FL, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg\u002Fday, three times a day, orally. For patients with baseline serum Vitamin C concentration ≥ 65 μmol\u002FL, continuously 900 mg\u002Fday, three times a day, orally.",[13],"Drug: Ascorbate",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"DRUG",[9],[19],"Vitamin C",[21],{"name":22,"affiliation":5,"role":23},"Guopei Luo, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Ying Yang, MD","CONTACT","86 21 64175590","1307","yangying@fudanpci.org",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":41,"coordinates":42},"Point",[43,44],121.45806,31.22222,{"lat":44,"lon":43},[47],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":23,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":51,"oldOrganization":51},"Guopei Luo","Professor",null,"100517542","phase-2-vitamin-c-to-quality-of-life-in-patients-with-terminal-stage-pancreatic-cancer-100517542",false,"NCT06018896","Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer","PTCA199-4","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document.\n* Age ≥ 18 years and ≤ 80 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Histologically or cytologically confirmed metastatic pancreas adenocarcinoma.\n* Tumor progression after two lines of chemotherapy.\n* Adequate organ performance based on laboratory blood tests.\n* Presence of at least of one measurable lesion in agreement to Response Evaluation Criteria in Solid Tumours (RECIST) criteria.\n* The expected survival ≥ 1 months.\n* Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.\n\nExclusion Criteria:\n\n* Active second primary malignancy or history of second primary malignancy.\n* The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.\n* Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc.\n* Pregnant or nursing women.\n* Glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n* Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results.\n* Renal insufficiency or dialysis\n* Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.\n* Patients who are unwilling or unable to comply with study procedures.","ALL","18 Years","80 Years",{"count":63,"type":64},20,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","The purpose of this study is to evaluate the efficacy of vitamin C in improving the quality of life for metastatic pancreatic cancer patients who are resistant to chemotherapy.",[70,71],"Metastatic Pancreatic Cancer","Terminal Cancer",[73,74,75,76],"ascorbate","anemia","quality of life","chemotherapy","2024-06-05",{"date":79,"type":80},"2024-06-06","ACTUAL",{"date":82,"type":80},"2023-08-25",{"date":84,"type":64},"2026-08-15",{"name":5,"class":6},1]